Interview with Dr James Garner, CEO of Kazia Therapeutics
-
Regulatory July 21, 2022Vivesto appoints Christer Nordstedt as acting CEO
-
Regulatory July 5, 2022Vivesto winds down its activities in Russia
-
Regulatory June 30, 2022Vivesto appoints Robert Maiorana as acting CFO
Vivesto published its Q1 2022 report on May 25, 2022, at 08.00 am CET.
Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program